therapy for AMFS has consisted of excision or amputation, with very limited use of radiation therapy or chemotherapy. In this report, we review the outcome of 17 patients with AMFS treated at our institution. Materials/Methods: A retrospective review of all cases of AMFS in the past 5 years identified in the Sarcoma Database in the Department of Radiation Oncology at our institution was conducted. Patients' treatment records and follow-up visits were reviewed. Results: Seventeen patients were identified. All of the patients underwent surgical resection: 15 excisions, 2 amputations. Positive margins after excisions were noted in 5 patients and were widely positive in 1 patient. Of the 17 patients, 15 patients received some form of radiation. Average total dose was 56.4 Gy. 8 patients received pre-operative RT alone, 6 patients received pre-operative RT and postoperative RT, and 1 patient received pre-operative RT and intraoperative RT. Average follow-up was 32.8 months. One patient presented with recurrent disease and was treated with excision, and pre and post operative RT. He is currently 23 months free of disease. No local recurrence was noted in the remaining patients. Of the 14 patients undergoing pre-op XRT, complete pathologic necrosis or no tumor was seen in one of the patients. No metastatic disease was noted in any of the patients. There was no significant radiation toxicity observed in any of the patients. Conclusions: Our data is consistent with local control of distal extremity sarcomas with excision and radiation therapy, suggesting that RT is an appropriate option in the limb sparing control of patients with AMFS, even those with positive margins.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.